-
1
-
-
0026436979
-
Schizophrenia: Manifestations, incidence and course in different cultures - a World Health Organization ten-country study
-
Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures - a World Health Organization ten-country study. Psychol Med Monogr Suppl 1992; 20: 1-97.
-
(1992)
Psychol Med Monogr Suppl
, vol.20
, pp. 1-97
-
-
Jablensky, A.1
Sartorius, N.2
Ernberg, G.3
-
2
-
-
22144432283
-
-
Saha S, Chant D, Welham J, McGrath J. A Systematic review of the prevalence of schizophrenia. PLOS Med 2005; 2(5): e141 http://www.pubmedcentral.gov/picrender.fcgi?artid=1140952&blobtype= pdf. Electronic citation accessed 2007-02-17.
-
Saha S, Chant D, Welham J, McGrath J. A Systematic review of the prevalence of schizophrenia. PLOS Med 2005; 2(5): e141 http://www.pubmedcentral.gov/picrender.fcgi?artid=1140952&blobtype= pdf. Electronic citation accessed 2007-02-17.
-
-
-
-
3
-
-
33745081916
-
The incidence and prevalence of schizophrenia varies with latitude
-
Saha S, Chant D, Welham J, McGrath J. The incidence and prevalence of schizophrenia varies with latitude. Acta Psychiatr Scand 2006; 114: 36-39.
-
(2006)
Acta Psychiatr Scand
, vol.114
, pp. 36-39
-
-
Saha, S.1
Chant, D.2
Welham, J.3
McGrath, J.4
-
4
-
-
33644774618
-
Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes. Findings from the 3-center ÆSOP study
-
Kirkbride JB, Fearon P, Morgan C, et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes. Findings from the 3-center ÆSOP study. Arch Gen Psychiatry 2006; 63: 250-258.
-
(2006)
Arch Gen Psychiatry
, vol.63
, pp. 250-258
-
-
Kirkbride, J.B.1
Fearon, P.2
Morgan, C.3
-
5
-
-
34547507435
-
-
National Institute of Mental Health. National Institutes of Health. Schizophrenia - Description of Symptoms and Causes. http://www.nimh.nih.gov/publicat/schizoph.cfm. Electronic citation accessed 2006-07-07.
-
National Institute of Mental Health. National Institutes of Health. Schizophrenia - Description of Symptoms and Causes. http://www.nimh.nih.gov/publicat/schizoph.cfm. Electronic citation accessed 2006-07-07.
-
-
-
-
7
-
-
0032908294
-
Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder
-
Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544-549.
-
(1999)
Am J Psychiatry
, vol.156
, pp. 544-549
-
-
Robinson, D.G.1
Woerner, M.G.2
Alvir, J.M.3
-
8
-
-
0028603313
-
A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse
-
Steingard S, Allen M, Schooler NR. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. J Clin Psychiatry 1994; 55: 470-472.
-
(1994)
J Clin Psychiatry
, vol.55
, pp. 470-472
-
-
Steingard, S.1
Allen, M.2
Schooler, N.R.3
-
9
-
-
0029082109
-
Symptoms, signs, and diagnosis of schizophrenia
-
Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet 1995; 346: 477-481.
-
(1995)
Lancet
, vol.346
, pp. 477-481
-
-
Andreasen, N.C.1
-
11
-
-
0033576175
-
Fortnightly review. Treatment of schizophrenia
-
McGrath J, Emmerson WB. Fortnightly review. Treatment of schizophrenia. Br Med J 1999; 319: 1045-1048.
-
(1999)
Br Med J
, vol.319
, pp. 1045-1048
-
-
McGrath, J.1
Emmerson, W.B.2
-
13
-
-
0036964515
-
Higher cardiovascular mortality with sertindole in ADROIT: A signal not confirmed
-
Moore N. Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int J Psychiatry Clin Pract 2002; (Suppl. 1): S11-420.
-
(2002)
Int J Psychiatry Clin Pract
, Issue.SUPPL. 1
-
-
Moore, N.1
-
14
-
-
0037832552
-
Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: The example of sertindole
-
Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003; 12: 271-281.
-
(2003)
Pharmacoepidemiol Drug Saf
, vol.12
, pp. 271-281
-
-
Moore, N.1
Hall, G.2
Sturkenboom, M.3
Mann, R.4
Lagnaoui, R.5
Begaud, B.6
-
15
-
-
0035666619
-
The pharmacovigilance of olanzapine: Results of a post-marketing surveillance study on 8858 patients in England
-
Biswasl PN, Wilton LV, Pearcel GL, Freemantle S, Shakir SA. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 2001; 15(4): 265-271.
-
(2001)
J Psychopharmacol
, vol.15
, Issue.4
, pp. 265-271
-
-
Biswasl, P.N.1
Wilton, L.V.2
Pearcel, G.L.3
Freemantle, S.4
Shakir, S.A.5
-
16
-
-
0034935090
-
Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine
-
Wilton LV, Heeley EL, Picketing RM, Shakir SA. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001; 15(2): 120-126.
-
(2001)
J Psychopharmacol
, vol.15
, Issue.2
, pp. 120-126
-
-
Wilton, L.V.1
Heeley, E.L.2
Picketing, R.M.3
Shakir, S.A.4
-
17
-
-
0030014564
-
The mortality experience of individuals on the Salford Psychiatric Case Register. I. All-cause mortality
-
Baxter DN. The mortality experience of individuals on the Salford Psychiatric Case Register. I. All-cause mortality. Br J Psychiatry 1996; 168: 772-779.
-
(1996)
Br J Psychiatry
, vol.168
, pp. 772-779
-
-
Baxter, D.N.1
-
18
-
-
0036773659
-
Neuroleptics and mortality in schizophrenia: Prospective analysis of deaths in a French cohort of schizophrenic patients
-
Montout C, Casadebaig F, Lagnaoui R, et al. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr Res 2002; 57: 147-156.
-
(2002)
Schizophr Res
, vol.57
, pp. 147-156
-
-
Montout, C.1
Casadebaig, F.2
Lagnaoui, R.3
-
19
-
-
0037009914
-
Rates of spontaneous reporting of adverse drug reactions in France
-
Begand B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002; 288: 1588.
-
(2002)
JAMA
, vol.288
, pp. 1588
-
-
Begand, B.1
Martin, K.2
Haramburu, F.3
Moore, N.4
-
20
-
-
1542309330
-
Mortality during use of sertindole and other anti-psychotics in the Netherlands and Belgium
-
Abstract 273
-
Sturkenboom MCJM, Picelli G, Moore N. Mortality during use of sertindole and other anti-psychotics in the Netherlands and Belgium. Pharmacoepidemiol Drug Saf 2001; 10: S-164. Abstract 273
-
(2001)
Pharmacoepidemiol Drug Saf
, vol.10
-
-
Sturkenboom, M.C.J.M.1
Picelli, G.2
Moore, N.3
-
21
-
-
34547503394
-
SCoP study (sertindole cohort: Prospective study): sertindole versus risperidone outcome study
-
Abstract 191
-
Verpillat P, Mittoux A, Schuck P, Kuhn F, Perquin L, Peuskens J. SCoP study (sertindole cohort: prospective study): sertindole versus risperidone outcome study. Pharmacoepidemiol Drug Saf 2004; 13: S-95, Abstract 191.
-
(2004)
Pharmacoepidemiol Drug Saf
, vol.13
-
-
Verpillat, P.1
Mittoux, A.2
Schuck, P.3
Kuhn, F.4
Perquin, L.5
Peuskens, J.6
|